TME Pharma NV (XPAR:ALTME) YoY EBITDA Growth : 86.40% (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is TME Pharma NV YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. TME Pharma NV's YoY EBITDA Growth for the quarter that ended in Dec. 2023 was 86.40%.

TME Pharma NV's EBITDA per Share for the six months ended in Dec. 2023 was €-0.42.

TME Pharma NV YoY EBITDA Growth Historical Data

The historical data trend for TME Pharma NV's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TME Pharma NV YoY EBITDA Growth Chart

TME Pharma NV Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

YoY EBITDA Growth

Get a 7-Day Free Trial

92.68

-124.94

-19.46

44.09

89.78

TME Pharma NV Semi-Annual Data
	Dec14	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
YoY EBITDA Growth	Get a 7-Day Free Trial													-17.69	11.87	66.43	91.28	86.40

TME Pharma NV YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

TME Pharma NV's YoY EBITDA Growth for the fiscal year that ended in Dec. 2023 is calculated as:

	YoY EBITDA Growth (A: Dec. 2023 )
=	(EBITDA per Share (A: Dec. 2023 )	-	EBITDA per Share (A: Dec. 2022 ))	/	\| EBITDA per Share (A: Dec. 2022 ) \|
=	(-1.011	-	-9.893)	/	\| -9.893 \|
=	89.78 %

TME Pharma NV's YoY EBITDA Growth for the quarter that ended in Dec. 2023 is calculated as:

	YoY EBITDA Growth (Q: Dec. 2023 )
=	(EBITDA per Share (Q: Dec. 2023 )	-	EBITDA per Share (Q: Dec. 2022 ))	/	\| EBITDA per Share (Q: Dec. 2022 )) \|
=	(-0.416	-	-3.058)	/	\| -3.058 \|
=	86.40 %

TME Pharma NV YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of TME Pharma NV's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

TME Pharma NV (XPAR:ALTME) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TME Pharma NV (XPAR:ALTME) » Definitions » YoY EBITDA Growth

Comparable Companies

Traded in Other Exchanges

0N6A:Germany

Address

Max-Dohrn-Street 8-10, Berlin, DEU, 10589

Website

https://www.tmepharma.com

TME Pharma NV is a clinical-stage biopharmaceutical company engaged in improving cancer treatment by targeting the tumor microenvironment and focusing on the improvement in the effectiveness of cancer therapies. Its product candidates are; NOX-A12 and NOX-E36 are based on a new class of drug first developed by TME Pharma called Spiegelmers, which offer specific advantages over other drug classes.

TME Pharma NV (XPAR:ALTME) Headlines

No Headlines